Chronic Total Occlusion of Coronary Left Main Artery Supplied by Right Collaterals under Vascular Endothelial Growth Factor Inhibitor Therapy
Published: 2023-08-18
Page: 328-332
Issue: 2023 - Volume 6 [Issue 1]
K. Chawki *
Department of Cardiology, IBN Rochd University Hospital, Morocco.
E. M. Rochd
Department of Cardiology, IBN Rochd University Hospital, Morocco.
M. Selmaoui
Department of Cardiology, IBN Rochd University Hospital, Morocco.
A. El Jazouli
Department of Cardiology, IBN Rochd University Hospital, Morocco.
M. Haboub
Department of Cardiology, IBN Rochd University Hospital, Morocco.
S. Arous
Department of Cardiology, IBN Rochd University Hospital, Morocco.
G. Bennouna
Department of Cardiology, IBN Rochd University Hospital, Morocco.
A. Drighil
Department of Cardiology, IBN Rochd University Hospital, Morocco.
R. Habbal
Department of Cardiology, IBN Rochd University Hospital, Morocco.
*Author to whom correspondence should be addressed.
Abstract
We report a rare case of a patient who despite being under anti VEGF : Bevacizumab , developed a large coronary collateral circulation completely supplying the chronic total occlusion of left main coronary artery.
Bevacizumab, a monoclonal antibody was the first potent angiogenic inhibitor , targeting vascular endothelial growth factor (VEGF)-A.
Some of it's important cardiovascular adverse events include arterial and venous thrombotic events, coronary artery disease and heart failure resulting from inhibition of endothelial regeneration.
Our patient developed dyspnea after 1 year of receiving bevacizumab with a chronic total occlusion of the left main coronary artery with the particularity of developing extensive collaterals despite the anti VEGF treatment she received.
Keywords: Coronary artery disease, vascular endothelial growth, myocardial dysfunction, Bevacizumab
How to Cite
Downloads
References
Meier P, Gloekler S, Zbinden R, Beckh S, de Marchi SF, Zbinden S, et al. Beneficial effect of recruitable collaterals: A 10-year follow-up study in patients with stable coronary artery disease undergoing quantitative collateral measurements. Circulation. 2007;116(9):975–83.
McEntegart MB, Badar AA, Ahmad FA, Shaukat A, MacPherson M, Irving J, Strange J, Bagnall AJ, Hanratty CG, Walsh SJ, Werner GS. The collateral circulation of coronary chronic total occlusions. EuroIntervention. 2016;11(14):e1596-603.
Valle M, Virtanen K, Hekali P, Frick MH. Survival with total occlusion of the left main coronary artery. Significance of the collateral circulation. Catheterization and Cardiovascular Diagnosis. 1979;5(3):269-75.
Vo MN, Brilakis ES, Kass M, Ravandi A. Physiologic significance of coronary collaterals in chronic total occlusions. Canadian Journal of Physiology and Pharmacology. 2015;93(10):867-71.
Dong W, Li J, Mi H, Song X, Jiao J, Li Q. Relationship between collateral circulation and myocardial viability of 18 F-FDG PET/CT subtended by chronic total occluded coronary arteries. Annals of Nuclear Medicine. 2018;32:197-205.
Ranpura V, Hapani S, Chuang J, et al. Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: A meta-analysis of randomized controlled trials. Acta Oncol. 2010;4:287-97.
Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005; 69(Suppl 3):25–33.
Scappaticci FA, Skillings JR, Holden SN, et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007;99:1232-9.
Zhu X, Wu S, Dahut WL, Parikh CR. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis. Am J Kidney Dis. 2007;49(2):186–93.
Zhou Yan et al. The role of the VEGF family in coronary heart disease. Frontiers in Cardiovascular Medicine. 2021;8:738325. DOI:10.3389/fcvm.2021.738325